Englewood Lab Balance Sheet Health
Financial Health criteria checks 6/6
Englewood Lab has a total shareholder equity of ₩114.9B and total debt of ₩11.1B, which brings its debt-to-equity ratio to 9.7%. Its total assets and total liabilities are ₩173.6B and ₩58.7B respectively. Englewood Lab's EBIT is ₩28.9B making its interest coverage ratio 60. It has cash and short-term investments of ₩17.9B.
Key information
9.7%
Debt to equity ratio
₩11.11b
Debt
| Interest coverage ratio | 60x |
| Cash | ₩17.89b |
| Equity | ₩114.92b |
| Total liabilities | ₩58.72b |
| Total assets | ₩173.64b |
Recent financial health updates
Recent updates
When Should You Buy Englewood Lab, Inc. (KOSDAQ:950140)?
Apr 16
There Are Reasons To Feel Uneasy About Englewood Lab's (KOSDAQ:950140) Returns On Capital
Mar 31If You Had Bought Englewood Lab (KOSDAQ:950140) Shares A Year Ago You'd Have Earned 106% Returns
Mar 17What Kind Of Shareholders Hold The Majority In Englewood Lab, Inc.'s (KOSDAQ:950140) Shares?
Feb 23These 4 Measures Indicate That Englewood Lab (KOSDAQ:950140) Is Using Debt Reasonably Well
Feb 05
Englewood Lab, Inc. (KOSDAQ:950140) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ?
Jan 20Is Englewood Lab, Inc. (KOSDAQ:950140) Potentially Undervalued?
Jan 02Returns On Capital At Englewood Lab (KOSDAQ:950140) Paint An Interesting Picture
Dec 15Are Englewood Lab's (KOSDAQ:950140) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Nov 26Financial Position Analysis
Short Term Liabilities: A950140's short term assets (₩131.5B) exceed its short term liabilities (₩51.4B).
Long Term Liabilities: A950140's short term assets (₩131.5B) exceed its long term liabilities (₩7.4B).
Debt to Equity History and Analysis
Debt Level: A950140 has more cash than its total debt.
Reducing Debt: A950140's debt to equity ratio has reduced from 47.9% to 9.7% over the past 5 years.
Debt Coverage: A950140's debt is well covered by operating cash flow (185.7%).
Interest Coverage: A950140's interest payments on its debt are well covered by EBIT (60x coverage).